In the ageing male, the prostate gland undergoes continuous microscopic cellular remodeling. Central to this process is the steroidogenic conversion of circulating free testosterone into dihydrotestosterone (DHT) through the catalytic action of the enzyme 5-alpha-reductase (5-AR).
Dihydrotestosterone binds to intracellular androgen receptors with roughly five times greater affinity than testosterone itself, remaining bound for a significantly longer biological half-life. Once inside the nucleus of prostatic stromal and epithelial cells, the DHT-receptor complex triggers transcription factors that stimulate local epidermal growth factors (EGF) and insulin-like growth factors (IGF), promoting tissue volume expansion.
Extracted from the ripe berries of the American dwarf palm (*Serenoa repens*), lipidosterolic compounds contain high concentrations of medium-chain free fatty acids (specifically lauric, oleic, and myristic acids) alongside plant phytosterols.
Biochemical assays confirm that these specific fatty acids non-competitively modulate both Type 1 and Type 2 isoenzymes of 5-alpha-reductase. Unlike synthetic pharmaceutical 5-AR inhibitors, standardised botanical extracts achieve this modulation locally within the prostatic tissue without substantially depressing circulating serum testosterone levels or causing systemic endocrine side effects.
Crude dried berry powders typically contain less than 10% active fatty acids by weight. Clinical efficacy demonstrated in landmark European trials relies strictly on supercritical CO₂ extracts standardised to contain 85% to 95% free fatty acids and sterols at an optimal daily dosage of 320 mg.
When *Serenoa repens* is co-administered with *Urtica dioica* root extract, complementary pharmacological actions occur. Stinging nettle root polysaccharides specifically bind to sex hormone-binding globulin (SHBG), preventing it from attaching to receptors on prostatic cell membranes. This synergistic interaction has been documented in numerous multicentre European trials (such as the PRO 160/120 clinical trials) to significantly enhance peak flow rates.